Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search

CDC Activities

From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels 

Scott D. Grosse, PhDa, Coleen A. Boyle, PhDa, Aileen Kenneson, PhDa, Muin J. Khoury, MD, PhDb, Benjamin S. Wilfond, MDc

line

References

  1. Serving the family from birth to the medical home: a report from the Newborn Screening Task Force convened in Washington, DC, May 10–11, 1999. Pediatrics. 2000;106:383–427
  2. Therrell BL Jr. U.S. newborn screening policy dilemmas for the twenty-first century. Mol Genet Metab. 2001;74:64–74
  3. Levy HL, Albers S. Genetic screening of newborns. Annu Rev Genomics Hum Genet. 2000;1:139–177
  4. Comeau AM, Larson C, Eaton RB. Integration of new genetic diseases into statewide newborn screening: New England experience. J Med Genet C Semin Med Genet. 2004;125:35–41
  5. Rinaldo P, Tortorelli S, Matern D. Recent developments and new applications of tandem mass spectrometry in newborn screening. Curr Opin Pediatr. 2004;16:427–433
  6. National Newborn Screening and Genetics Resource Center. U.S. national screening status report. Available at: http://genes-r-us.uthscsa.edu/nbsdisorders.pdf This reference links to a non-governmental website. (last accessed 3/2007)
  7. American College of Medical Genetics. Newborn screening: toward a uniform screening panel and system—report for public comment. Available at: http://mchb.hrsa.gov/screening. (last accessed 3/2007)
  8. Bailey DB Jr. Newborn screening for fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10:3–10
  9. Parsons EP, Clarke AJ, Bradley DM. Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection. Eur J Paediatr Neurol. 2004;8:145–153
  10. Pass KA, Lane PA, Fernhoff PM, et al. U.S. newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation—statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr. 2000;137(4 suppl):S1–S46
  11. Brownson RC, Baker EA, Leet TL, Gillespie KN. Evidence-Based Public Health. New York, NY: Oxford University Press; 2003
  12. Kohatsu ND, Robinson JG, Torner JC. Evidence-based public health: an evolving concept. Am J Prev Med. 2004;27:417–421
  13. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 suppl):21–35
  14. Briss PA, Brownson RC, Fielding JE, Zaza S. Developing and using the Guide to Community Preventive Services: lessons learned about evidence-based public health. Annu Rev Public Health. 2004;25:281–302
  15. Waisbren SE, Mahon BE, Schnell RR, Levy HL. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics. 1987; 79:351–355
  16. National Research Council. Committee for the Study of Inborn Errors of Metabolism. Genetic Screening: Programs, Principles, and Research. Washington, DC: National Academy of Sciences; 1975
  17. Clayton EW. What should be the role of public health in newborn screening and prenatal diagnosis? Am J Prev Med. 1999;16:111–115
  18. Cunningham GC. Two years of PKU testing in California: the role of the laboratory. Calif Med. 1969;110:11–16
  19. US Congress, Office of Technology Assessment. Healthy Children: Investing in the Future. Washington, DC: US Government Printing Office; 1988
  20. Hodes RM. Testing newborns for adenosine deaminase deficiency not cost effective. N Engl J Med. 1981;305:1530
  21. Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist AS. Long-term follow-up of a cohort of children with alpha-1- antitrypsin deficiency. J Pediatr. 1990;116:248–251
  22. Consensus Development Conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987; 258:1205–1209
  23. Olney RS. Preventing morbidity and mortality from sickle cell disease: a public health perspective. Am J Prev Med. 1999;16: 116–121
  24. Gaston HH, Verter JJ, Wood G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314:1593–1599
  25. Wilson JMG, Jungner G. Principles of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968
  26. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, eds. Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: National Academy of Sciences; 1994
  27. US General Accounting Office. Newborn Screening: Characteristics of State Programs. Washington, DC: Government Printing Office; March 2003. Document GAO-03-449. Available at: http://www.gao.gov/new.items/d03449.pdf . (last accessed 3/2007)
  28. Atkinson K, Zuckerman B, Sharfstein JM, Levin D, Blatt RJ, Koh HK. A public health response to emerging technology: expansion of the Massachusetts newborn screening program. Public Health Rep. 2001;116:122–131
  29. Grosse S, Gwinn M. Assisting states in assessing newborn screening options. Public Health Rep. 2001;116:169–172
  30. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996
  31. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess. 2004;8(12):1–121
  32. Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children: minutes of second meeting— Washington, DC, September 22–23, 2004.
  33. Save Babies Through Screening Foundation, Inc. Steps to get supplemental screening. Available at: http://www.savebabies.org/NBS/snbs.php This reference links to a non-governmental website. (last accessed 3/2007)
  34. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1–36
  35. Baily MA. Final Report: Fairness in the Distribution of Costs and Benefits in Newborn Screening Programs. HRSA contract 01- MCHB-70A with the Hastings Center, Garrison, NY: February, 2003
  36. Grosse SD. Does newborn screening save money? The difference between cost-effective and cost-saving interventions. J Pediatr. 146:168–170
  37. Holtzman NA. Routine screening of newborns for cystic fibrosis: not yet. Pediatrics. 1984;73:98–99
  38. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development: proceedings of a 1997 workshop. MMWR Recomm Rep. 1997;46(RR-16):1–24
  39. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics. 2001;107: 1–13
  40. Koscik RL, Farrell PM, Kosorok MR, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics. 2004;113:1549–1558
  41. Accurso FJ, Sontag MS, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005;147(3 suppl):S37–S41
  42. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004; 17:59–67
  43. Wilfond BS, Gollust SE. Policy issues for expanding newborn screening programs: the cystic fibrosis newborn screening experience in the United States. J Pediatr. 2005;146:668–674
  44. Comeau AM, Parad R, Gerstle R, et al. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005;147(3 suppl):S89–S93
  45. Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998; 26:81–88
  46. Mischler EH, Wilfond BS, Fost N, et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics. 1998;102:44–52
  47. Farrell MH, Farrell PM. Newborn screening for cystic fibrosis: ensuring more good than harm. J Pediatr. 2003;143:707–712
  48. Wilfond BS, Parad RB, Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr. 2005;147(3 suppl):S109–S113
  49. American Academy of Pediatrics, Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics. 2001; 107:1451–1455
  50. Pelias MK, Markward NJ. Newborn screening, informed consent, and future use of archived tissue samples. Genet Test. 2001;5:179–185
  51. Mandl KD, Feit S, Larson C, Kohane IS. Newborn screening program practices in the United States: notification, research, and consent. Pediatrics. 2002;109:269–273
  52. Fant KE, Clark SJ, Kemper AR. Completeness and complexity of information available to parents from newborn-screening programs. Pediatrics. 2005;115:1268–1272
  53. Leonard JV, Dezateux C. Screening for inherited metabolic disease in newborn infants using tandem mass spectrometry. BMJ. 2002;324:4–5
  54. Cunningham G. The science and politics of screening newborns. N Engl J Med. 2002;346:1084–1085
  55. Khoury MJ, Little J. Human genome epidemiologic reviews the beginning of something HuGE. Am J Epidemiol. 2000;151: 2–3
  56. Lindegren ML, Kobrynski L, Rasmussen SA, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep. 2004;53(RR-1):1–29
  57. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Application of population screening principles to genetic screening for adult-onset conditions. Genet Test. 2001;5:201–211
  58. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies: lessons from cystic fibrosis. JAMA. 1993;270:2948–2954
  59. Agency for Healthcare Research and Quality. Evidence-based practice centers overview. September, 2004. Available at: http://www.ahrq.gov/clinic/epc. (last accessed 3/2007)
  60. Campbell E, Ross LF. Parental attitudes regarding newborn screening of PKU and DMD. Am J Med Genet A. 2003;120: 209–214
  61. American Society of Human Genetics, American College of Medical Genetics. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 1995;57:1233–1441
  62. Ross LF. Predictive genetic testing for conditions that present in childhood. Kennedy Inst Ethics J. 2002;12:225–244  
Page last reviewed: April 10, 2007 (archived document)
Page last updated: November 2, 2007
Content Source: National Office of Public Health Genomics